Latest Cetuximab Stories
MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc.
Enrollment for a Phase I study is open for patients with a form of colorectal cancer, where the patients will be treated with a cancer biologic called REOLYSIN Calgary, Alberta (Vocus/PRWEB) January 18, 2011 Colorectal cancer is the third leading cause of cancer death among both men and women in the US.
SEATTLE, WA, Dec. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux(R)).
SAN FRANCISCO and ILLKIRCH, France, Dec.
BURLINGTON, Mass., Dec.
Stereotactic body radiotherapy (SBRT), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, may effectively control and treat head and neck cancers when combined with the chemotherapy Cetuximab.
A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer.
Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations.
Taking back the years the fears and anxieties of having cancer may have brought are possible.
Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy.
- An armed gangster.